leadf
logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics appointed to the board of US National Cannabis Roundtable

The company will be represented on the NCR board by its US chief executive officer Oludare Odumosu.

Zelira Therapeutics Ltd - Zelira Therapeutics appointed to the board of the US National Cannabis Roundtable
The NCR is a non-partisan advocacy group focusing on federal cannabis reform in the US

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) has been appointed to the board of directors of the National Cannabis Roundtable (NCR) in Washington DC, US. 

The company will be represented on the NCR board by its US chief executive officer Oludare Odumosu MPH, Ph.D.

NCR is a non-partisan advocacy group focusing on federal cannabis reform in the US. 

As part of its reform agenda, it is seeking to remove federal restrictions that prohibit medical research involving cannabis and to allow companies to operate legally in the US-based cannabis industry. 

Excited to have Zelira

Zelira's US CEO Oludare Odumosu.

Trulieve chief executive officer and NCR board of directors second vice chair Kim Rivers said: “We are excited to have Zelira join our growing roundtable.

“Their focus on research and health is ground-breaking and will help us really show the breadth and potential of the cannabis industry”.

Bringing breakthrough therapeutics to market

Dr Odumosu said: “The manner that the federal government handles reform will have fundamental impacts on the people we serve.

"Our company is committed to bringing breakthrough therapeutics to market and we need to have the regulatory framework that will allow the research to expand and grow on a Federal/National level."

Expertise invaluable

NCR first vice-chair Chanda Macias said: “I have worked extensively with Dr Odumosu and his colleagues at Zelira Therapeutics.

”I am personally thrilled that he will be joining us at the table in Washington.

“His biopharmaceutical expertise will be invaluable as my colleagues and I work to expand access to clinically proven cannabis medicines for patients around the country while also addressing important issues of reform at the federal level.

NCR

The honorary chairman of the NCR is John Boehner, the former Speaker of the US Congress.

In addition, the roundtable announced the appointment of a new honorary co-chair, Kathleen Sebelius, who is the former governor of Kansas and former Human Services Secretary, under former President Barack Obama.

Quick facts: Zelira Therapeutics Ltd

Price: 0.064 AUD

ASX:ZLD
Market: ASX
Market Cap: $76.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics sees 'multiple shots on goal' with a number of revenue...

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) deputy chairman Harry Karelis speaks to Proactive's Andrew Scott soon after announcing a strategic consolidation of its operations which sees leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the...

1 week, 2 days ago

2 min read